1st Quarter - Report
AVENUE SOLUTIONS for VIROPHARMA INCORPORATED
Firm
Client
Income
$40,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues related to bioequivalence for locally-acting drugs; H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012; Senate working drafts of PDUFA (Prescription Drug User Fee Act) Reauthorization
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH MACDONALD BARNETT | — |
| TRACY SPICER | — |
| AMY TEJRAL | — |
Health Issues HCR
Issues related to bioequivalence for locally-acting drugs; H.R. 3988, Generic Drug and Biosimilar User Fee Act of 2012; Senate working drafts of PDUFA (Prescription Drug User Fee Act) Reauthorization
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH MACDONALD BARNETT | — |
| TRACY SPICER | — |
| AMY TEJRAL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.